Wellnex Life Limited
WNX · AIM · Retail · mcap £3.7m · 4.5p 2 open situations →
- EV
- £7.9m
- EV / EBIT
- –
- Net debt
- £4.6m
- FCF yield
- -39.4%
- Revenue
- £12.6m
- Share price 1y
- −64%
- Insiders 12m
- no deals
- Next report
- around 26 Feb
Wellnex Life is an Australian consumer health company that owns and sells over-the-counter brands and makes products for others under contract. It sells mainly through Australian retailers and pharmacies and is expanding into the UK, New Zealand and other markets.
Open · 2
Sale of Pain Away
Includes Two-pillar strategy and cost reset – FY26 audited: loss cut, cash positive in 2H
Wellnex signed a binding agreement on 6 Aug 2026 to sell Pain Away to Mentholatum (Rohto group) for up to A$21.3m cash (A$19.8m upfront plus earn-out of up to A$1.5m). Shareholders approved at the EGM on 8 Sep 2026, and completion with the upfront price settled was announced on 11 Sep 2026. Proceeds go to retiring debt and working capital.
- Price
- A$19.8m upfront plus earn-out of up to A$1.5m (per earlier announcements) 11 Sep 2026 ↗
- Buyer
- Mentholatum Australasia Pty Ltd 11 Sep 2026 ↗
- Business sold
- Pain Away; FY25 unaudited revenue $13.38m, EBITDA about $4.36m (per earlier announcements) 11 Sep 2026 ↗
- Use of money
- Retire debt and support working capital for continuing operations 11 Sep 2026 ↗
- Escrow
- A$1m of the completion payment held in escrow 6 Aug 2026 ↗
- Conditions
- Shareholder approval at EGM on 8 September 2026; sunset date 30 October 2026 1 Sep 2026 ↗
Next: further shareholder update on options for value
- 11 Sep 2026 Completed; upfront price settled
- 1 Sep 2026 Binding agreement; awaiting shareholder approval
- 6 Aug 2026 Binding agreement signed; awaiting shareholder approval
- 31 Jul 2026 Loan repayment extended; funding still open
Two-pillar strategy and cost reset
Part of Sale of Pain Away – Completed; upfront price settled, closed 11 Sep 2026
The turnaround began with the October 2025 reset. Audited FY26 (1 Sep 2026) shows revenue up 5.1% to A$24.8m, net loss down 70.8% to A$4.5m and an EBITDA loss of A$1.7m (FY25: A$12.1m). Positive operating cash flow came in Q3 and Q4. The savings target is above A$1m annualised.
- Q4 gross profit
- $2.0m, up 33.3% from $1.5m 31 Jul 2026 ↗
- Q4 operating cash flow
- $63k positive; H2 FY26 about $0.5m versus $3.1m outflow in H1 31 Jul 2026 ↗
- FY26 receipts
- $22.0m; H2 up 28% on H1 31 Jul 2026 ↗
- Revenue
- A$24.8m, up 5.1% (FY25: A$23.6m) 1 Sep 2026 ↗
- Net loss
- A$4.5m, down 70.8% from A$15.6m 1 Sep 2026 ↗
- EBITDA loss
- A$1.7m vs about A$12.1m in FY25 1 Sep 2026 ↗
Next: Completion of Pain Away sale and retained-business plan
- 1 Sep 2026 FY26 audited: loss cut, cash positive in 2H
- 31 Jul 2026 Q4 revenue rebound; second positive cash quarter
- 30 Apr 2026 First positive operating cash flow; revenue down
- 12 Mar 2026 Turnaround continues under new Interim Executive Chair
Closed · 1
Company filings. Not investment advice.